Fig. 6

Synergistic ferroptosis/glycolysis interference by FesiRNAPNPs. a Schematic of FesiRNAPNPs for synergistic ferroptosis with energy metabolism interference in tumors. b TEM images of FesiRNAPNPs. c Western blot analysis of GAPDH protein levels in FesiRNAPNP-treated CT26 cells. d Cytotoxicity of FeGPNPs and FesiRNAPNPs against CT26 cells after 24 h of incubation. Concentration is expressed as Fe ion content. e Western blot analysis of GPX4, NRF2, Keap1, P62, and GAPDH protein expression levels in FesiRNAPNPs-treated CT26 cells. f ATP concentration in FeGPNP- and FesiRNAPNP-treated CT26 cells. g Tumor size change during therapy. h H&E (Scale bar: 100 μm) and TUNEL (Scale bar: 50 μm) staining of tumor sections in different groups. Group I: PBS-treated; Group II: FeGPNP-treated via tail vein injection; Group III: FesiRNAPNP-treated via tail vein injection